OBJECTIVE: @entity439 repair (EVAR) of @entity1028 ( @entity1028 ) has gained widespread use through a solid reputation of safety and effectiveness. However, some issues, such as endoleaks and sac growth over time, still arise as important concerns. Antiplatelet therapy, mandatory as secondary prevention of @entity65 , may play a role in both phenomena by interfering with blood clotting properties and the inflammatory process associated with @entity11557 . We analyzed whether different antiplatelet therapies were independent risk factors for @entity1070 (T2E) persistence and midterm sac growth after EVAR. METHODS: All @entity1 with T2E detected in the first post-EVAR control were included, except those without at least 1  year  of complete follow-up. Data for demographics, clinical comorbidities, EVAR devices, and antiplatelet therapies were  recorded. All @entity1 underwent routine follow-up with contrast-enhanced tomography at 1  month, 6  months, 12  months, and annually thereafter. A three-dimensional rendering of each @entity1070 was performed for detailed volumetry. Main outcomes were @entity1070 persistence at 6  months and sac growth >5  mm at end of follow-up. RESULTS: During a 9-year period, 87 @entity1 with initial T2E were monitored for a mean of 41.5  months. On discharge, @entity8834 were prescribed to 50, @entity1397 to 16, and multiagent therapy or anticoagulation to 9; no therapy was given to 12. No significant differences in comorbidities or baseline @entity11557 characteristics were found between groups. At 6  months thereafter, 59% (n  = 51) of the initial T2Es persisted. At end of follow-up, 32 @entity1 had sac growth >5  mm (37%). Sac growth was significantly less frequent in the group treated with @entity8834 (26% vs 60%; P  = .004). Cox proportional hazards model reinforced the role of @entity8834 as protectors for sac growth over time (hazard ratio, 0.34; 95% confidence interval, 0.13-0.87; P  = .024), whereas T2E nidus volume and @entity1070 complexity behaved like independent risk factors. CONCLUSIONS: Antiplatelet therapy with @entity8834 appears to be linked to a decreased risk of sac growth >5  mm over time in @entity1 with T2Es detected right after EVAR. Population-based cohort studies are mandatory to confirm this finding and to guide a potential recommendation.

Effect of antiplatelet therapy on aneurysmal sac expansion associated with @entity1070 after XXXX repair.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity11557 :: ('MESH:C565230', 'Disease') :: ['AAA'] @entity8834 :: ('MESH:D012459', 'Chemical') :: ['salicylates'] @entity1070 :: ('MESH:D057867', 'Disease') :: ['endoleak', 'type II endoleak'] @entity1397 :: ('MESH:C055162', 'Chemical') :: ['clopidogrel'] @entity439 :: ('MESH:D000783', 'Disease') :: ['Endovascular aneurysm'] @entity1028 :: ('MESH:D017544', 'Disease') :: ['abdominal aortic aneurysms', 'AAAs'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']
@entity439 :: (MESH:D000783,Disease) :: ['endovascular aneurysm']
